

MDS UK PATIENT SUPPORT GROUP

Unaudited Financial Statements

Year ended 31st March 2021

Registered Charity Number: 1145214

MDS UK PATIENT SUPPORT GROUP

Report of the Trustees for the year ended 31st March 2021

Index

Page Number	Description
3 to 12	Report of the Trustees
13	Unaudited Statement of Financial Activities
14	Unaudited Balance Sheet
15 to 18	Unaudited Notes to the Financial Statements

Registered Charity Number: 1145214

MDS UK PATIENT SUPPORT GROUP

Report of the Trustees for the year ended 31st March 2021

The trustees, submit their report together with the financial statements for the year ending 31st March 2021.

Results

The results for the year and the financial position of the charity ("MDSUK") are shown in the annexed financial statements. The charity is a non-profit Charitable Incorporated Organisation and is a registered charity (No, 1145214).

The financial statements have been prepared in accordance with the accounting policies and comply with the Charity's governing document, the Charities Act 2011 and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard (FRS 102).

Chair's Report

The past year has been one of considerable achievement for the Charity. However, our achievements were sadly overshadowed at the end of the financial year by the effect of the Covid-19 pandemic which has placed a major burden on our financial resources.

Last year we set ourselves a number of strategic targets aimed at strengthening the Charity and broadening our range of activities for the benefit of our members. A major commitment was that of entering the field of clinical research. Such an undertaking had been discussed at length by our Central Board. A major consideration was that of finance, as sponsorship of research is extremely expensive, plus the likelihood of a positive outcome is always uncertain. Taking these factors into consideration, we decided that as it was something that many of those suffering from MDS had asked for, it was a rational way to use our financial reserves. Following the advertising of the proposed Ph.D. research, we received several suitable applications and after careful analysis of the proposed research, assisted by haematological clinicians, a decision was made to award the project to Queen Mary's College, Belfast University. A major reason for the award was that the research was to be based on the repair of damaged DNA, which occurs in all blood cancers. Thus, a positive outcome from the research could have significant implications for the treatment of blood cancers. A Ph.D. student was subsequently selected by the University and commenced the research in January 2020. Our Charity was congratulated by Professor Mufti (Head of Haematology at Kings College Hospital) for taking this significant step into clinical research. Unfortunately, the spread of Covid-19 has delayed the progression of the research.

With the assistance of a specialist fundraising company and following a careful analysis of our previous fundraising initiatives and that of similar Charities, a broad fundraising strategy was designed and, prior to the interruption of the pandemic, was being followed. The fundraising company also advised on the selection of a Fundraising Officer. Utilising our financial reserves, the selected individual was recruited as an employee with the objective of 'driving' the strategy.

Again, the intervention of the pandemic has severely limited the range of fundraising initiatives possible. As an example, a major fundraising event involving celebrities, at a well-known national sports location, was planned for later in the year. This, together with many of the external physical events which have been a regular source of income for us, have had to be cancelled.

MDS UK PATIENT SUPPORT GROUP

Report of the Trustees for the year ended 31st March 2021

However, work continues on identifying virtual fundraising opportunities.

Following a period of improving income streams, a decision was also made to recruit additional staff as employees. The decision was based on several factors. All previous staff members had worked for the Charity on a self-employed basis, which was felt to be detrimental to the commitment, longevity and necessary learning of the individuals concerned. Two new members of staff were subsequently employed as an Office Manager and Administrative Assistant prior to the pandemic. The appointments have enabled us to make improvements in our information technology systems together with improved communication.

The expansion of our locally based support groups continued in the past year with new groups established e.g. in Kent. The pandemic has meant that Support Groups were unable to meet in person and consequently a system of virtual support groups has been devised. To some extent the greater use of meetings via media communication platforms, such as Zoom, have enabled us to expand the types of specific support offered, e.g. for carers and the bereaved, as well as those who had previously been unable to attend local support groups due to their residence in sparsely populated areas where there were no other MDS patients. We continue to explore the formation of additional specialist support groups to enable vital support to be offered during the ongoing lockdown. It must be remembered that Governmental easing of lockdown restrictions has little significance for MDS patients, as they remain at high risk whilst the threat of Covid-19 or Covid derivatives continues and consequently virtual meetings remain our primary method of communication.

The Charity, led by its CEO, has again played a major part in continuing to champion, lead and involve itself in organisations involved in blood cancers and rare cancers both in the United Kingdom and abroad. Our CEO has detailed our involvement in her report. Suffice it to say that MDS UK Patient Support Group continues to 'punch above its weight' both in National and International organisations in which it is involved.

Whilst the Charity has taken major decisions over the past year to expand and diversify, the impact of Covid has severely impacted us, probably to a greater extent than larger charities. As previously indicated, our venture into clinical research, taking on new members of staff as employees and utilising a fundraising specialist company to devise a fundraising strategy has been expensive. Our income has traditionally relied on support from those affected by MDS, who regularly undertook physical challenges throughout the year, as well as pharmaceutical grants. The pandemic has caused almost all planned external activities to be cancelled and we are having to adapt and devise new inventive ways of raising funds. However, despite the downturn in income streams occurring at an inopportune time for us, we have the necessary reserves to enable us to cover the likely deficit for the current year.

Once again, I would like to thank all those associated with MDS UK, including the members of our Board, all volunteers, patients and carers, members of staff and those within the NHS who have assisted us throughout the year and without whom the Charity could not exist.

Edward Peel L LB (Hons)
Chair MDS UK

MDS UK PATIENT SUPPORT GROUP

Report of the Trustees for the year ended 31st March 2021

Our purposes and activities

The Charity's principal activities during the year under review relate to the support of individuals suffering Myelodysplastic Syndrome ("MDS"), which is a rare blood cancer. The activities were previously carried on by a trust with the same name and were taken over by the company with effect from 1st April 2012.

The objects of the Charity are:

- (i) To relieve the sickness and preserve, promote and protect the health of sufferers of MDS in the United Kingdom through the provision of support, education and practical advice.
- (ii) To advance the education of the general public in the United Kingdom in all areas in relation to MDS.
- (iii) To promote and support scientific research into MDS and its treatment together with the care of MDS sufferers and those disposed to the development of MDS.

Report of the Chief Executive

Achievements and performance

The Charity's main activities are the operation and provision of the following services for individuals affected by MDS in the UK and Ireland:

- Maintaining a website with information about all aspects of MDS
- Running a telephone helpline and e-mail support
- Setting up and running regional and national group meetings at regular intervals
- Maintaining networking platforms for patients/relatives (Facebook and a chat forum)
- Maintaining other social media platforms (Twitter and Instagram)

In addition, MDS UK takes part in other related activities, to better serve and assist those affected by MDS:

- HTA – Health Technology Appraisals with NICE, SMC – to enable access to treatment
- Providing patient expertise at EMA (European Medicines Agency) level
- Participation in clinical conferences, to raise awareness of MDS and support services to haematologists and clinical staff
- Participation in blood cancer events, to raise awareness amongst the general public
- Participation in PPI (Patient and Public Involvement) review work at NCRI level, as well as national care and treatment guidelines for MDS.
- Patient expert and PPI reviews for clinical trials (commercial and institutions)

MDS (UK) has continued to increase its advocacy work at both UK and European levels where it affects UK issues. All of these activities provide support and information to MDS sufferers and their families.

MDS UK PATIENT SUPPORT GROUP

Report of the Trustees for the year ended 31st March 2021

Achievements this year included:

- MDS UK Patient Survey – initial data was accepted as a scientific poster by the main haematology conferences in UK (BSH), Europe (EHA). This survey is the largest scientifically representative sample of MDS patients in the UK and a proportion of data was analysed and presented. This work has since generated great further interest from other stakeholders, but changes in staffing, as well as the advent of COVID-19, including provisions to work from home, have prevented further work from taking place in this financial year. The remaining data will be analysed end of 2021, COVID-permitting.
- MDS World Awareness Day was marked by a successful campaign involving poetry about MDS, with contributions across the UK and the rest of the world. The MDS World Awareness Day will continue to be marked in the future, in partnership with the international MDS Alliance.
- MDS UK took part in the Make Blood Cancer Visible Campaign, to mark Blood Cancer Awareness Month in September.
- The charity concentrated on strengthening its local patient groups, which often are more convenient for elderly patients to attend. 1 further new group was created, and the potential for 4 new ones. A national patient forum event this year was not possible, due to the need to train new staff, and the advent of COVID-19. Several local meetings had to be cancelled due to COVID-19. In March 2020, MDS UK started exploring ways to implement virtual patient meetings for our members.
- The Charity has promoted its services and activities at multiple educational events throughout the UK, to groups of patients, nurses, physicians and pharma industry, through presentations and information stands.
- The start of the 3rd edition of the MDS Patient Handbook (in collaboration with Leukaemia CARE and Bloodwise) was postponed due to COVID-19.
- Two editions of an extended version of the MDS UK Newsletter were published, in June 2019 and March 2020, with a new Newsletter editor.
- The choice of the PhD topic was completed, with assistance of the scientific advisory board. A candidate was identified and started work – but progress was interrupted by COVID-19.
- In terms of clinical trials, MDS UK has maintained and further strengthened the level of PPI (Patient and Public Involvement) work with the NCRI MDS group of experts. A unique model of partnership was co-developed, enabling a much broader participation of patients to provide their perspectives and opinions about a new university led feasibility

MDS UK PATIENT SUPPORT GROUP

Report of the Trustees for the year ended 31st March 2021

trial. This model of cooperation will be recommended as a future best practice model for PPI.


- MDS UK has completed the PPI review for the latest update for the National BSH (British Society of Haematology) Treatment Guidelines for MDS.
- MDS UK participated in further commercial trial reviews and research projects for pharmaceutical companies, from a PPI perspective.
- MDS UK submitted evidence for a NICE HTA in January 2020 for a new MDS drug. The HTA was subsequently cancelled, with no new date announced so far. MDS UK has been actively pursuing discussions regarding compassionate use or early access to this new drug.
- The specific Clinical Trial information service continues to be popular and accessed by patients, but also haematologists, and the Principal Investigators who can struggle to recruit rare sub-types of patients. Pharmaceutical companies have also been glad to see trial information being provided, due to slow or difficult recruitment circumstances.
- MDS UK continues to be members of various groups and umbrella organisations, including: BCA (Blood Cancer Alliance), Cancer 52, which aim to raise awareness of blood cancer issues and rare cancers respectively.
- MDS UK continued to be actively involved at European and international level through organisations such as EMA (European Medicines Agency) ESH (European School of Haematology), EHA (European Haematology Association) and ASH (American Society of Haematology), together with other MDS overseas groups. MDS Alliance activities have been maintained, with MDS UK coming to the end of its 2-year chairmanship in December 2019. MDS UK continues to lead several working groups within MDS Alliance.
- MDS UK, via the MDS Alliance, has continued to work on the European project on rare diseases called ERN's (European Reference Networks). The ERN dedicated to rare haematology conditions is called EuroBloodNet and the main purpose is to share best practice across Europe as well as facilitate cross-border healthcare and a wider access to clinical trials. However, COVID-19 has significantly slowed down progress with this project.
- Via MDS Alliance, MDS UK maintained its active contribution to the scientific public-private partnership project, HARMONY, which represents a unique data-sharing collaboration across European research centres which aims to provide answers to specific unresolved research queries.
- In terms of staffing, MDS UK revised the office set-up, by directly employing personnel through PAYE. The Office Manager position has been maintained, and a dedicated Membership Officer role was created to streamline processes, due to an increased level

Report of the Trustees for the year ended 31st March 2021

of activities and membership level. A full-time Fundraising Officer staff member was appointed, taking over from a previous part-time volunteer. Significant training time was dedicated to new staff in early 2020.

HR tasks were allocated to a committee member for the time being.

- A Fundraising Strategy was developed further, to ensure longer term sustainability of the charity and its services, however, plans and progress had to be revised due to COVID-19.
- Significant revisions to the IT and database setup were implemented in late 2019, to improve work processes. However, COVID-19 forced a complete change of work practices and hardware, by having to operate remotely, as staff needed to work from home. A new IT support company was appointed for this process.
- COVID-19 significantly interfered with the end of the financial year, doubling the amount of helpline and email workload. The pandemic also forced a complete overhaul of working practices, job descriptions, and re-training of existing and new staff, to respond to the need and demand for new services being accessible virtually and remotely.
- The Charity changed from a company limited by guarantee to a charitable incorporated organisation (CIO). For many years charities in England and Wales have had to make do with legal structures that were originally intended for other purposes, such as trusts and limited companies. The legal framework within which companies operate was never intended for charitable organisations, and there is a constant tension between the regulations which charities face under the Charities Acts and the obligations which are imposed on companies by company law. The CIO is intended to provide charities with the benefits of incorporation to registered charities within a more attractive legal framework that is regulated purely by the Charities Commission. By adopting the CIO we have simplified our regulation and reporting requirements and have taken the opportunity to adopt a new constitution and code of conduct more appropriate to the charity we operate today.



Sophie Wintrich
Chief Executive

MDS UK PATIENT SUPPORT GROUP

Report of the Trustees for the year ended 31st March 2021

Financial Review

The following figures were taken from the full accounts approved on 29th October which have been examined by an independent examiner. This part of the Trustee's annual report comments on the key features of these accounts. In this section we explain how we raised the money and then how we spent it.

Money received - £180,512. Money spent - £155,999

Overall, we ended with a surplus of £24,513 compared to a deficit of £215,362 in 2019/20.

Money received: sources of funds

Total income for the year of £180,512 was 92% higher than the previous year (2019/20)- £93,977) Donations of £148,298 from members of the public and relatives of patients were greater than last year thanks partly to the 20-20 fundraising campaign. We were fortunate to receive £15,151 income from legacies, (2019/20 £0). A grant of £10,000 was received from Janssen and £750 from Novartis. Both were unrestricted and complied with the Code of Practice for the UK Pharmaceutical Industry.

Money spent:

Expenditure for the year of £155,999 was £153,340 less than last year which included a provision of £173,046 for the research grant. Covid has affected the amount of face to face activities replaced by Zoom sessions at a significantly lower cost. There was an increase in staff costs as seconded or contract staff were replaced by our own employees.

The surplus for the year of £24,513 has been added to unrestricted reserves which now amount to £189,937.

Going concern

Reserves are needed to bridge the gap between the spending and receiving of income and to support the activities of the Charity in the event of a significant reduction in income. From time to time the trustees review the required level of reserves. The trustees have reviewed the impact of COVID-19 on the ability of the charity to raise funds and the increase in demand for our services. The trustees have considered continued uncertainty due to Covid 19, the level of funds held, and the expected level of income and expenditure for the 12 months following the approval of these financial statements. They have concluded that the budgeted income and expenditure with the existing level of free reserves is sufficient for the Charity to be able to continue as a going concern

MDS UK PATIENT SUPPORT GROUP

Report of the Trustees for the year ended 31st March 2021

Reference and administrative details

Charity number: 1145214
Registered Office: Haematology - Bessemer Wing (Ground Floor), Kings
College Hospital, Denmark Hill, London SE5 9RS.

Our Advisors

Examiner: David King, FCA The Dell, Old Farm Rd, Hampton, TW12 3RJ
Bankers: CAF Bank Ltd
Charity Bank
Co-Operative Bank Ltd
CCLA Investment Management Ltd
Hampshire Trust Bank
Scottish Widows Bank Ltd
Nationwide Building Society
Redwood Bank Ltd

Trustees

The trustees serving during the year and since the year end were as follows:

Edward Peel
Sophie Wintrich
Fiona Pirilla (resigned 21st May, 2021)
Don Barrett
Russell Cook
Chris Charlwood
Claudia Richards
Tony Allen (appointed 1st October, 2021)
Lin Holder (appointed 1st October, 2021)

Key management personnel:

Chief Executive: Sophie Wintrich

MDS UK PATIENT SUPPORT GROUP

Report of the Trustees for the year ended 31st March 2021

Structure, Governance and Management

Governing document

As explained in the Chief Executive's Report the Charity changed from a company limited by guarantee to a Charitable Incorporated Organisation (CIO) governed by a constitution dated 23rd October 2020. The members of the CIO who are trustees of the charity are listed above.

Appointment of Trustees

Existing trustees propose new trustees. The number of trustees shall not be less than three and a maximum of eight.

Organisation

The board of trustees administers the charity and normally meets quarterly. There is also a management committee of all the members of the CIO which meets quarterly. A Chief Executive is appointed by the trustees.

To facilitate effective operations, the Chief Executive has delegated authority, within terms of delegation approved by the trustees, for operational matters including finance and employment.

Equal Opportunities

The Charity operates a policy of equal opportunities. All recruitment, employment practice and service delivery within the organisation is carried out according to the principles of equal opportunities.

Risk Management

The trustees have assessed the risks to which the charity is exposed and are satisfied that systems and procedures are in place to mitigate, where possible, those risks identified.

This is an especially important exercise at the current time in view of the risks surrounding COVID-19. The principal risk is that the impact on fundraising could reduce the level of activities undertaken by the charity.

Register of Interests

A register has been set up in which trustees are required to declare their outside interests, specifically directorships of other boards.

Trustee's responsibilities in relation to the financial statements

The trustees are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and regulations.

Charity law requires the trustees to prepare the financial statements for each financial year.

The financial statements have been prepared in accordance with the accounting policies set out in notes to the accounts and comply with the charity's governing document, the Charities Act 2011 and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard (FRS 102) for Smaller Entities.

MDS UK PATIENT SUPPORT GROUP

Report of the Trustees for the year ended 31st March 2021

Under charity law the trustees must not approve the financial statements unless they give a true and fair view of the state of affairs of the company and of the incoming resources and outgoing resources of the charity for that period

In preparing these financial statements, the trustees are required to:

- (i) select suitable accounting policies and then apply them consistently.
- (ii) observe the methods and principles in the Charities Statement of Recommended Practice (SORP);
- (iii) make judgments and accounting estimates that are reasonable and prudent.
- (iv) prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

The trustees are responsible for keeping proper accounting records that are sufficient to show and explain the charity's transactions and disclose with reasonable accuracy at any time the financial position of the charity and to enable them to ensure that the financial statements comply with the Charities Act 2011. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website.

This report has been prepared in accordance with the provisions applicable to charities.

By Order of the board of trustees



Edward Peel (Chair)

Date

Unaudited Statement of Financial Activities (Incorporating Income and Expenditure Account) for the year ended 31st March, 2021.

		2021	2020
		£	£
	Note	Total	Total
Income from			
Donations and similar incoming resources	3	148,298	82,202
Legacies	3	15,151	-
Grants	4	10,750	6,500
Investment income	5	1,104	1,766
Other Income		5,209	3,509
Total income		180,512	93,977
Expenditure on			
Raising Funds	6	3,952	17,861
Charitable activities	7	152,047	116,927
Provision for Research grant	9	-	173,046
Governance Costs	11	-	1505
Total expenditure		155,999	309,339
Net income		24,513	-215,362
Reconciliation of funds			
Total funds brought forward		165,424	380,786
Total funds carried forward		189,937	165,424

All amounts relate to continuing activities

The notes on pages 15 to 18 form part of these financial statements

Unaudited Balance sheet
As at 31st March 2021.

		2021	2020
		£	£
	Note	Total	Total
Current assets:			
Debtors	13	7,199	4,710
Current asset investments	14	298,526	322,423
Cash at bank and in hand		42,835	34,385
Liabilities: Amounts falling due within one year			
Creditors and accruals	15	-15,091	-26,800
Total Net Assets		333,469	334,718
Provision for research grant		143,532	169,294
The Funds of the Charity		189,937	165,424
Unrestricted income funds	16	189,937	165,424
Total funds		189,937	165,424

The trustees are responsible for the preparation of the accounts. The trustees consider that an audit is not required for this year under section 144(2) of the Charities Act 2011 (the 2011 Act) and that an independent examination is needed.

The trustees acknowledge their responsibilities for complying with the requirements of the Act in respect of accounting records and the preparation of financial statements. The financial statements have been prepared in accordance with the provisions of the Charities Act 2011 and guidance provided by the Charity Commission.

The financial statements on pages 13 to 18 were approved by the board of trustees on the 19th November, 2021 and authorised for issue and signed on its behalf by:

E Peel
Chair

Registered Charity Number: 1145214

Interest on funds held on deposit is included when receivable and the amount can be measured reliably. All the charity's investment income arises from money held in interest bearing deposit accounts regulated by the Prudential Regulating Authority and covered by the Government's Financial Services Compensation Scheme (FSCS).

Resources expended

Liabilities are recognised as soon as there is a legal or constructive obligation committing the Charity to that expenditure, it is probable that settlement will be required and amount of the obligation can be measured reliably. All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category. Irrecoverable VAT is reported as part of the expenditure to which it relates.

Research Grants

Grants payable are payments made to third parties in furtherance of the charitable objects of the charity. In the case of an unconditional grant offer this is accrued once the recipient has been notified of the grant award. Provisions for grants are made where there is uncertainty as to the timing of the grant or the amount of grant payable.

Charitable activities

Costs of charitable activities includes expenditure incurred in the delivery of activities and services for beneficiaries and all the support costs as shown in note 10.

Governance costs

Governance costs comprise all costs involving public accountability of the Charity and its compliance with regulation and good practice. These costs include legal and professional fees and the costs of the AGM and governance meetings.

Corporation Tax

The Charity is exempt from tax on income and gains falling within section 505 of the Taxes Act 1988 or section 252 of the Taxation of Chargeable Gains Act 1992 as any surplus or gains are applied for charitable purposes.

Reserves

The Trustees have reviewed the policy on reserves considering the uncertainties around the impact of Covid 19 on our income and expenditure in the short and medium term. The Trustees have decided to use reserves to maintain our service levels and to meet new demands to respond to Covid 19. We expect to incur a surplus for the year ending 31 March 2022 as we have been informed of a considerable legacy the exact amount of which is yet to be finalised. Any surplus reserves will be designated to promote and support scientific research into MDS

Cash flow Statement

Due to its size, the charity is not required to present a Cash flow Statement under the Financial Reporting standards.

1) Accounting policies

The Charity is a Charitable Incorporated Organisation (CIO) registered in England & Wales and has no share capital. The charity's registered office address is Haematology - Bessemer Wing, Kings College Hospital, Denmark Hill, London SE5 9RS. Its charity number is 1145214.

Basis of preparation

The financial statements were prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standards applicable in the UK and Republic of Ireland (FRS 102), effective 1 January 2019 - Charities SORP (FRS 102).

Assets and liabilities are recognised at historical cost or transaction value.

Preparation of accounts on a going concern basis.

The Trustees are satisfied that the CIO is a going concern and that these accounts should be prepared on that basis. With the continuing uncertain economic outlook the Trustees and CEO have put measures in place to extend and improve fundraising. The Trustees have considered the level of funds held and the expected level of income and expenditure for 12 months following the approval of these financial statements. The budgeted income and expenditure is sufficient with the unrestricted reserves of £189,937 for the charity to continue as a going concern.

Income Recognition

Income represents income attributable to the activities of the Charity when the Charity becomes entitled to the donation or similar income and any conditions for receipt are met, and the trustees are reasonably certain that they will receive it and the value can be reliably measured. Grants received without any restriction on entitlement are recognised in full upon award.

Legacy gifts are recognised following the granting of probate when the Charity has been notified in writing of both the amount and settlement date.

Donated professional services or facilities are recognised as income when the Charity has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use of the item is probable and that economic benefit can be measured reliably. In accordance with the Charities SORP (FRS 102), the general volunteer time of our team of volunteers is not recognised.

Unaudited notes to the financial statements as at 31st March 2021

2) Trustees' Remuneration

The charity reimbursed Kings College Hospital Trust for emoluments of £34,913 and pension and NI contributions of £8,648 in respect of Sophie Wintrich, the Chief Executive. The other trustees neither received or waived any emoluments. The charity meets the expenses incurred by trustees in carrying out their duties. During the year no trustees had expenses met by the charity.

3) Donations, legacies and similar incoming resources.

	2021 £	2020 £
Donations (including Gift Aid)	148,298	82,202
Legacies	15,151	-
	<u>163,449</u>	<u>82,202</u>

4) Grants

Novartis	750	-
Janssen	10,000	6,500
	<u>10,750</u>	<u>6,500</u>

5) Investment Income

Bank Interest Received	<u>1,104</u>	<u>1,766</u>
------------------------	--------------	--------------

6) Costs of raising funds

Advertising and promotion	1,070	4,809
Consultant	2,260	8,432
Event Costs	622	4,620
	<u>3,952</u>	<u>17,861</u>

7) Costs of activities for charitable objectives

Reimbursed staff costs (2 secondees)	44,658	43,561
Staff costs	66,974	-
Consultant	-	1,250
Donor database development/maintenance	2,760	1,650
Website	11,765	10,540
Newsletters	-	26,893
Literature and Information Sheets	3,066	1,262
Myelo's Hope MDS Animation	14,975	-
National Forums	-	-
Local Support Groups	14	1746
Survey	853	-
Conference Participation	-	1,717
Travel and expenses	13	355
Support costs (Note 10)	6,969	27,953
	<u>152,047</u>	<u>116,927</u>

Unaudited notes to the financial statements as at 31st March 2021

8) Staff Costs and Emoluments

	2021	2020
	£	£
Salaries	60,380	11,329
Social security costs	4,940	868
Pension costs	1,654	283
	<u>66,974</u>	<u>12,480</u>

9) Research Grant

Following a formal selection process Queens University Belfast was chosen to receive the first scientific research grant from the Charity to improve treatment for Myelodysplastic Syndrome. The Charity awarded a grant of £173,046 to fund a four year PHD programme. A total of £25,761 was reimbursed during the year. A provision for the full amount of the grant was made in the previous year in accordance with the Charities SORP (FRS 102)

	2021	2020
	£	£
Support Staff	-	12,480
Contract staff	-	9,740
Payroll costs	616	-
Stationery and postage	251	1,034
Telephone and broadband	1,128	1,158
Office computer and software	3,377	2,050
Recruitment	-	777
Sundry expenses	1,597	714
	<u>6,969</u>	<u>27,953</u>

11) Governance costs

AGM & governance meetings	-	1,505
	<u>0</u>	<u>1,505</u>

12) Taxation

The CIO is a registered charity with no liability to tax arising in the year.

13) Debtors

Gift Aid Recoverable	5,729	1,815
Prepayments	1,350	2,700
Other	120	195
	<u>7,199</u>	<u>4,710</u>

14) Current asset investments

Nationwide Building Society Deposit	75,958	75,871
CCLA Charities Deposit	48,609	83,526
Co-Op Instant Access	65	64
Hampshire Trust	87,939	87,091
Redwood Bank Deposit	10,000	-
Scottish Widows Deposit	75,955	75,871
	<u>298,526</u>	<u>322,423</u>

15) Creditors

Paye	325	151
Accruals	14,766	26,649
	<u>15,091</u>	<u>26,800</u>

16) Funds

Unrestricted funds of £189,937

Designated	-	-
Undesignated	189,937	165,424
	<u>189,937</u>	<u>165,424</u>

MDS UK PATIENT SUPPORT GROUP

Independent examiner's report to the trustees of MDS UK Patient Support Group ('the charity')

I report to the charity's trustees on my examination of the accounts of the charity for the year ended 31 March 2021.

Responsibilities and basis of report

As the charity's trustees you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the Act').


I report in respect of my examination of the charity's accounts carried out under section 145 of the 2011 Act and in carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent examiner's statement

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the charity as required by section 130 of the Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



D H King BSc FCA
Chartered Accountant
The Dell,
Old Farm Road
Hampton, Middlesex, TW12 3RJ

25 November 2021